PB 3 of 2015
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2015 (No. 1)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 24 January 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2015 (No.1).
 
(2)                This Instrument may also be cited as PB 3 of 2015.
 
2              Commencement
This Instrument commences on 1 February 2015.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
[1]           Part 1, Division 1, Section 4 , definition of medication for the treatment of HIV or AIDS
substitute:
                     (a)  abacavir;
                     (b)  abacavir with lamivudine;
                     (c)  abacavir with lamivudine and zidovudine;
                     (d)  atazanavir;
                     (e)  azithromycin;
                     (f)  clarithromycin;
                     (g)  darunavir;
                     (h)  didanosine;
                     (i)  doxorubicin, pegylated liposomal;
                     (j)  efavirenz;
                     (k)  emtricitabine;
                     (l)  enfuvirtide;
                     (m)  etravirine;
                     (n)  fosamprenavir;
                     (o)  foscarnet;
                     (p)  ganciclovir;
                     (q)  indinavir;
                     (r)  lamivudine;
                     (s)  lamivudine with zidovudine;
                     (t)  lopinavir with ritonavir;
                     (u)  maraviroc;
                     (v)  nevirapine;
                     (w)  raltegravir;
                     (x)  rifabutin;
                     (y)  rilpivirine
                     (z)  ritonavir;
                     (za)  saquinavir;
                     (zb)  stavudine;
                     (zc)  tenofovir;
                     (zd)  tenofovir with emtricitabine;
                     (ze)  tenofovir with emtricitabine and efavirenz;
                     (zf)  tenofovir with emtricitabine and rilpivirine;
                     (zg)  valaciclovir;
                     (zh)  valganciclovir;
                     (zi)  zidovudine.
[2]           Schedule 1, entry for Cidofovir
omit:
Cidofovir
Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial
Injection
Vistide
GI
EMP
C1610 C3322
 
4
3
D
 
[3]           Schedule 3, entry for Cidofovir
omit:
Cidofovir
C1610
 
Where the patient is receiving treatment at/from a private hospital
Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome
Compliance with Written or Telephone Authority Required procedures

 
C3322
 
Where the patient is receiving treatment at/from a public hospital
Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome
Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 3322